VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ALKSAlkermes plc
$55.08$9.2B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksALKSCash Flow

Alkermes plc (ALKS) Cash Flow Statement

30Y historyFree accessUpdated daily

Free cash flow generation remains erratic, evidenced by a wide margin variance ranging from a low of 3.6% in 2024Q1 to a peak of 44.2% in 2025Q4.

ALKS Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Mar'13Mar'12Mar'11Mar'10Mar'09Mar'08Mar'07Mar'06Mar'05Mar'04Mar'03Mar'02Mar'01Mar'00Mar'99Mar'98Mar'97Mar'96
Cash from Operations421.94M520.75M439.12M401.35M21.04M101.72M82.84M72.08M99.28M19.19M-63.8M-40.36M11.14M126.55M-2.48M-5.91M-12.25M34.59M42.42M83.73M116.53M-74.25M-98.25M-48.75M-42.68M-17.99M-33.03M-14.25M-1.14M-17.18M-5.5M
Operating CF Margin %-35.28%28.19%24.13%1.89%8.67%7.98%6.16%9.07%2.12%-8.56%-6.42%1.8%21.99%-0.43%-1.51%-6.56%19.4%12.98%34.78%48.56%-44.57%-129.06%-124.82%-90.3%-33.25%-58.95%-62.17%-3.35%-54.76%-27.74%
Operating CF Growth %-83.2%18.59%9.41%1807.21%-79.31%22.78%14.94%-27.4%417.36%130.08%-58.08%-462.33%-91.2%5198.75%57.97%51.78%-135.41%-18.47%-49.33%-28.15%256.93%24.42%-101.55%-14.21%-137.27%45.54%-131.8%-1153.59%93.38%-212.27%39.56%
Net Income152.72M241.66M367.07M355.76M-158.27M-48.17M-110.86M-196.62M-139.31M-157.94M-208.44M-227.16M-30.06M24.98M-113.68M-45.54M-39.63M130.5M166.98M9.45M3.82M-73.92M-102.38M-106.9M-61.35M-16.87M-68.05M-41.06M-9.77M-18.8M-13.7M
Depreciation & Amortization19.74M27.16M28.53M74.93M77.86M78.65M81.85M80.41M103.66M98.52M94.26M85.6M98.09M73.75M93.68M8.65M25.03M10.27M12.14M11.99M10.88M10.62M10.91M9.32M10.5M7.7M6.43M21.62M2.65M2.57M2.4M
Stock-Based Compensation-22.81M096.64M100.91M94.25M87.62M90.16M100.98M105.36M83.92M94.4M97.34M59.58M41.29M028.83M000000000000000
Deferred Taxes-2.51M28.77M40.52M-99.9M-32.8M5.08M9.98M-319K10.62M7.23M-9.69M-37.58M-19.19M-2.11M-14.56M841K94K3.71M0000000000000
Other Non-Cash Items132.53M104.03M4.51M6.33M27.28M4.08M-1.43M22.22M26.37M-7.66M-7.12M-40.53M-108.13M10.66M4.34M1.86M3.74M-1.73M-138.25M31.68M5.95M13.15M3.73M21.31M5.82M-1.67M29.96M245.13K-507.6K14.5K0
Working Capital Changes75.79M119.12M-98.15M-36.66M12.71M-25.55M13.13M65.41M-7.42M-4.88M-27.2M81.98M10.86M-15.44M-1.1M8.45M-15.4M-122.96M1.56M30.61M95.89M-24.11M-10.51M27.51M2.35M-7.15M-1.38M4.94M6.49M-958.33K5.8M
Change in Receivables-14.94M30.17M-56.34M-44.51M25.25M-38.01M-18.05M29.98M-58.63M-42.49M-35.62M-16.45M-17.4M-14.32M0-14.01M000000000000000
Change in Inventory-12.31M-14.06M3.09M-2.71M-31.02M-24.77M-22.93M-13.08M-2.67M-30.19M-26.38M19.62M-31.24M-6.58M-4.88M5.21M-4.04M-5.14M-1.45M-12.14M-3.78M-3.07M000000000
Change in Payables102.57M100.89M-57.97M23.01M15.53M43.31M59.04M34.85M46.74M72.66M45.87M76.16M56.9M000000000000000000
Cash from Investing286.39M295.5M-111.31M53.36M-64.54M-66.2M-11.48M-141.83M-22.2M-18.36M127.24M-43.49M-263.4M-68.15M-417.16M5.63M28.01M45.36M61.97M-30.08M-137.87M-38.78M-80.88M31.8M42.07M21.19M-194.51M4.54M-113.05M-56.8M-11.9M
Capital Expenditures-30.31M-40.42M-33.48M-48.05M-38.26M-29.02M-42.22M-90.94M-69.43M-51.3M-43.66M-52.88M-33.65M-22.22M-16.99M-9.4M-15.79M-5.5M-21.89M-36.3M-28.66M-17.82M-15.1M-46.27M-33.38M-10.02M-5.76M-24.06M-7.99M-2.24M-5.6M
CapEx % of Revenue1.94%2.74%2.15%2.89%3.44%2.47%4.06%7.77%6.34%5.68%5.85%8.42%5.44%3.86%2.95%2.41%8.46%3.09%6.7%15.08%11.94%10.69%19.84%118.48%70.63%18.52%10.27%104.99%23.58%7.15%28.24%
Acquisitions1.08M2.79M97.98M0485K-713K2.75M-7.97M507K162K-15M50.5M27.19M193K-494.77M0-8M0012.57M122K252K784.24K6.06M371.38K005.38K1.08M00
Investments-------------------------------
Other Investing00461K354K1.27M8.94M4.53M10M507K162K194K50.5M44.37M-1.12M35K395K248K7.72M0-98K176K30K-98.49K-118.94K-100.31M-521.46K-131.82K-2.64M-17.32K10.5K2.4M
Cash from Financing11.63M12.38M-494.14M-289.71M-1.57M29.07M-2.17M6.76M-1.62M4.08M-58.17M40.89M308.76M-45.04M464.85M-40.65M-23.33M-94.3M-83.65M-6.73M7.43M150.62M116.6M73.37M10.74M-3.3M224.54M15.16M114.87M76.31M16.8M
Debt Issued (Net)00-291.79M-3M-3M20.32M-2.84M-2.84M-743K0-65.81M-6.75M-6.75M-83.46M-83.46M443.32M-45.4M-23.49M-83.44M-1.58M-1.78M-1.12M147.59M113.19M41.47M5.02M-5.63M-7.2M15.6M3.08M1.66M
Equity Issued (Net)-17.15M12.38M-200.28M-11.71M1.43M8.75M672K9.61M0000248.41M-11.67M004.74M-2.68M-10.94M-82.19M-4.95M8.56M3.03M3.41M31.9M5.72M9.59M247.5M7M112.8M74.65M
Dividends Paid0000000000000000000000000000000
Share Repurchases-31.03M-31.03M-200.28M-28.47M-18.2M-16.57M-7.7M-9.32M-19.62M-16.43M-13.47M-25.9M-12.84M-11.67M0-3.68M0-2.68M-18M-93.35M-12.49M00000-24.88K0000
Other Financing28.78M0-2.06M-275M0000-877K4.08M7.64M47.64M67.1M50.09M38.42M21.52M17.32M2.84M80K122K000-43.23M-62.63M-14.04M-7.27M-6.53M99.77M-39.56M-59.51M
Net Change in Cash-399.81M828.63M-166.32M165M-45.07M64.58M69.19M-62.99M75.47M4.92M5.27M-42.95M56.5M13.36M45.21M-40.93M-7.57M-14.35M20.74M46.92M-13.91M37.59M-62.58M56.46M10.1M-177.36K-3.01M5.42M696.25K2.35M-600K
Free Cash Flow391.63M480.33M405.64M353.31M-17.21M72.69M40.62M-18.86M29.85M-32.11M-107.46M-93.24M-22.51M104.33M-19.47M-15.31M-28.03M29.09M20.53M47.42M87.87M-92.07M-113.35M-95.02M-76.07M-28.01M-38.79M-38.31M-9.13M-19.42M-11.1M
FCF Margin %25.07%32.55%26.04%21.24%-1.55%6.19%3.91%-1.61%2.73%-3.55%-14.41%-14.84%-3.64%18.13%-3.38%-3.93%-15.02%16.32%6.28%19.7%36.62%-55.27%-148.9%-243.3%-160.93%-51.77%-69.23%-167.16%-26.93%-61.91%-55.98%
FCF Growth %-18.68%18.41%14.81%2152.79%-123.68%78.95%315.34%-163.2%192.96%70.12%-15.25%-314.17%-121.58%635.87%-27.2%45.4%-196.38%41.66%-56.7%-46.03%195.44%18.77%-19.29%-24.92%-171.59%27.79%-1.23%-319.6%52.98%-74.94%-14.43%
FCF per Share2.362.852.402.08-0.110.450.26-0.120.19-0.21-0.71-0.62-0.150.76-0.14-0.13-0.290.310.210.460.85-0.95-1.26-1.16-1.18-0.44-0.65-0.75-0.19-0.42-0.30
FCF Conversion (FCF/Net Income)2.56x2.15x1.20x1.13x-0.13x-2.11x-0.75x-0.37x-0.71x-0.12x0.31x0.18x-0.37x5.07x-0.10x0.05x0.27x-0.87x0.33x0.50x12.34x-19.45x1.31x0.48x0.40x0.29x1.96x0.21x0.03x1.37x0.29x
Interest Paid0023.01M22.75M13.56M6.9M8.29M012.53M11.14M12.46M12.32M12.49M07.66M21.66M1.68M4.92M15.34M000000000000
Taxes Paid002.59M44.24M20.75M1.89M620K0754K2.99M5.53M705K2.8M05.92M10.07M60K114K860K000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetHealthy
Cash FlowDeteriorating
Top Statement Risk

Royalty stream arbitration uncertainty

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Masked by Volatility

As reported in recent financial statements, ALKS exhibits significant variance in cash conversion, with the OCF/NI ratio reaching an extreme 4.40 in 2025Q1, suggesting that reported net income frequently fails to capture the underlying cash-generating capacity of the company's core CNS and royalty business segments.

The wide divergence between net income and operating cash flow indicates that non-cash items and working capital swings are heavily distorting the bottom line. Investors should monitor whether this disconnect reflects genuine operational efficiency or merely the timing of milestone payments and royalty receipts.

FCF Margin Volatility Remains Elevated

Based on the provided cash flow data, ALKS's free cash flow margins have fluctuated wildly, ranging from a low of 3.6% in 2024Q1 to a peak of 44.2% in 2025Q4, highlighting a lack of consistent cash generation despite the company's high-margin royalty-heavy business model.

This erratic trajectory suggests that the company's cash flow is highly sensitive to the timing of revenue recognition and potential arbitration outcomes. The inability to maintain a stable FCF margin complicates long-term valuation and suggests that cash flow predictability remains a significant hurdle for the firm.

Working Capital Swings Drive Liquidity

According to historical cash flow filings, working capital changes have been a primary driver of quarterly cash flow, with a notable $91.4M inflow in 2025Q4 contrasting sharply with the $66.3M outflow observed in 2024Q1, indicating significant volatility in the company's cash conversion cycle.

These large swings suggest that the company's cash position is heavily influenced by the timing of accounts receivable collections and inventory management. Such fluctuations may indicate that the business is susceptible to payment delays from partners or shifts in channel inventory levels.

Capital Allocation Shifts Toward Buybacks

As evidenced by recent financial disclosures, ALKS has prioritized share repurchases, including a $115.6M outlay in 2024Q3, while simultaneously navigating the spin-off of its oncology business, which appears to be a strategic pivot toward returning capital to shareholders rather than reinvesting in internal R&D.

The aggressive use of cash for buybacks during periods of earnings volatility warrants further investigation into management's long-term capital allocation strategy. Investors should consider whether these repurchases are intended to offset dilution or if they signal a lack of high-return internal investment opportunities.

ALKS — Frequently Asked Questions

Quick answers to the most common questions about buying ALKS stock.

How much cash does Alkermes plc (ALKS) generate from operations?

Alkermes plc (ALKS) generated $520.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Alkermes plc's free cash flow?

Alkermes plc (ALKS) generated $480.3M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Alkermes plc's capital expenditure (CapEx)?

Alkermes plc (ALKS) spent $40.4M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Alkermes plc distribute cash to shareholders?

In 2025, Alkermes plc (ALKS) spent $31.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.